Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors
- 31 May 2009
- journal article
- research article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 9 (5), 645-648
- https://doi.org/10.1016/j.intimp.2009.02.004
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Clinical Evaluation of M30 and M65 ELISA Cell Death Assays as Circulating Biomarkers in a Drug-Sensitive Tumor, Testicular CancerNeoplasia, 2008
- Optimisation of circulating biomarkers of cell death for routine clinical useAnnals of Oncology, 2008
- The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survivalLung Cancer, 2007
- Cell death modalities: classification and pathophysiological implicationsCell Death & Differentiation, 2007
- Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasmaCancer Chemotherapy and Pharmacology, 2007
- Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAPBritish Journal of Cancer, 2006
- Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cyclesBritish Journal of Cancer, 2006
- Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot StudyCancer Investigation, 2006
- Keratin 8/18 breakdown and reorganization during apoptosisExperimental Cell Research, 2004
- Caspase Cleavage of Keratin 18 and Reorganization of Intermediate Filaments during Epithelial Cell ApoptosisThe Journal of cell biology, 1997